<DOC>
	<DOCNO>NCT00931086</DOCNO>
	<brief_summary>An expanded access trial belimumab name patient participate LBRA99 .</brief_summary>
	<brief_title>Expanded Access Trial Belimumab Antibody RA Patients Who Were Previously Treated Under HGS Protocol LBRA99</brief_title>
	<detailed_description>An expanded access trial belimumab name patient Rheumatoid Arthritis ( RA ) experience continued benefit HGS Protocol LBRA99 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>1 . Have clinical judgment investigator , experience significant clinical benefit belimumab treatment HGS Protocol LBRA99 . 2 . Over course study 60 day last dose study agent , woman intact uterus postmenopausal must agree practice medically accept method contraception . 3 . Over course study 60 day last dose study agent , men must agree practice medically accept method contraception . 4 . Have ability understand requirement study , provide write informed consent ( include consent use disclosure researchrelated health information ) , comply require study visit . 1 . Had previously treat belimumab LBRA99 discontinue treatment prior HGS ' decision terminate LBRA99 . 2 . Had clinical evidence significant , unstable uncontrolled , acute chronic disease due RA ( ie , cardiovascular , pulmonary , anemia , gastrointestinal , hepatic , renal , neurological , cancer infectious disease ) could , opinion principal investigator , put patient undue risk . 3 . Are pregnant female nursing mother .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
</DOC>